
Caregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.
Pediatricians increasingly are recognizing a mandate to treat pain aggressively. Psychotropic drugs have new pediatric uses, broadening clinicians' options.






